A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

NCT04453930 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: Camrelizumab，an engineered anti-PD-1 antibody
DRUG: Platinum
DRUG: Irinotecan
DRUG: Apatinib

Sponsor

Peking Union Medical College Hospital